Journal
EXPERT OPINION ON BIOLOGICAL THERAPY
Volume 8, Issue 7, Pages 911-922Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14712598.8.7.911
Keywords
AAV; Ad; adenovirus; adeno-associated virus; gene therapy; heart; lentivirus; myocardium; plasmid
Ask authors/readers for more resources
Background: Cardiac gene therapy is approaching reality, with clinical trials entering Phase II/III. Even so, challenges exist to improve the efficacy of even the most successful therapies. Objective: The merits of different gene therapy vectors are weighed to assess the current feasibility of each in specific cardiac applications. Major obstacles are discussed, along with recent advances in vector development to overcome or circumvent those difficulties. Methods: This review focuses primarily on gene delivery via naked DNA, adenovirus, lentivirus, and adeno-associated virus (AAV) vectors. Conclusion: Gene therapy via adenovirus and AAV vectors has developed into a promising option for the treatment of heart disease. The merits of gene therapy compared with emerging stem cell and microRNA-based treatments are discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available